Press Releases
Atrium Innovations Updates its Development Strategy for the Wobenzym® Brand in Germany
Download
>>Quebec City (Quebec), September 3, 2009 – Atrium Innovations
Inc. (TSX: ATB), a leading
developer, manufacturer and marketer of science-based and professionally supported
products
for the Health and Nutrition industry, today announced various initiatives to
support the
development of its Wobenzym® brand in Germany.
Atrium announces that Mucos Pharma, a subsidiary of Atrium, has initiated the
phase out of
Wobenzym® N in Germany earlier than initially anticipated. Concurrently, Mucos
Pharma is
launching a new marketing campaign for Wobenzym® P, a natural enzyme-based product
with
an active OTC drug registration. Wobenzym® P will be commercialized like its
predecessor,
Wobenzym® N, as systemic enzyme therapy. As planned, Mucos Pharma intends to
launch a
new formulation of Wobenzym® to be sold as a food supplement in Germany and other
Western European countries in early 2010.
Conference call
Atrium will hold a conference call about its Wobenzym® commercialization strategy
in Germany
on September 3, 2009 at 8:45 a.m. Eastern time. Participants may access the call
by using the
following numbers: 1-888-231-8191 or 1-647-427-7450 (international and local
calls),
conference number: 28576925. A replay of the call will also be available on Atrium’s
website for
a period of 30 days.
About Atrium
Atrium Innovations Inc. is a recognized leading developer, manufacturer and marketer
of
science-based and professionally supported products for the Health & Nutrition
industry. The
Company focuses primarily on growing segments of the health and nutrition markets
which are
benefiting from the trends towards healthy living and the ageing of the population.
Atrium
markets a broad portfolio of finished products through its highly specialized
sales and marketing
network in more than 35 countries, primarily in North America and Europe. Atrium
has over 800
employees and operates seven manufacturing facilities. Additional information
about Atrium is
available on its website at www.atrium-innovations.com.
Cautionary Note and Forward-Looking Statements
This press release contains certain forward-looking statements with respect to
the Company.
These forward-looking statements, by their nature, necessarily involve risks
and uncertainties
that could cause actual results to differ materially from those contemplated
by these forward-
looking statements. The Company considers the assumptions on which these forward-looking
statements are based to be reasonable, but cautions the reader that these assumptions
regarding future events, many of which are beyond its control, may ultimately
prove to be
incorrect since they are subject to risks and uncertainties that affect the Company.
For
additional information with respect to these and other factors, see the Company’s
quarterly and
annual filings with the Canadian securities commissions. The Company disclaims
any intention
or obligation to update or revise any forward-looking statements, whether as
a result of new
information, future events or otherwise, other than as required by law.
Investor Relations:
Mario Paradis
Vice President and Chief Financial Officer
Tel.: 418 652-1116
email Mario Paradis
Media Relations:
Frédéric Tremblay
Edelman
Tel.: 514 844-6665, ext. 231
email Frederic Tremblay